These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22562584)

  • 1. Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone.
    Siniscalchi A; Tendas A; Morino L; Dentamaro T; De Bellis A; Perrotti A; de Fabritiis P; Musto P; Caravita T
    Support Care Cancer; 2012 Jul; 20(7):1585-7. PubMed ID: 22562584
    [No Abstract]   [Full Text] [Related]  

  • 2. Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.
    Allegra A; Alonci A; Penna G; Russo S; Gerace D; Greve B; D'Angelo A; Catena S; Musolino C
    Hematol Oncol; 2012 Mar; 30(1):41-5. PubMed ID: 21702057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
    Boruah PK; Bolesta S; Shetty SM
    Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
    Gozzetti A; Musto P; Defina M; D'Auria F; Papini G; Statuto T; D'Arena G; Bocchia M
    Br J Haematol; 2012 May; 157(4):497-8. PubMed ID: 22296516
    [No Abstract]   [Full Text] [Related]  

  • 5. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia.
    Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
    Leuk Lymphoma; 2015 Jan; 56(1):232-5. PubMed ID: 24884320
    [No Abstract]   [Full Text] [Related]  

  • 6. Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
    Ueda S; Kubo M; Matsuura N; Matsunaga H; Kataoka S; Maeda T; Inui Y; Kawata S; Kanakura Y
    Intern Med; 2013; 52(11):1235-8. PubMed ID: 23728562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
    Tamura S; Koyama A; Shiotani C; Kurihara T; Nishikawa A; Okamoto Y; Fujimoto T
    Intern Med; 2014; 53(11):1171-5. PubMed ID: 24881743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenytoin-associated hypersensitivity syndrome with features of DRESS and TEN/SJS.
    Viera MH; Perez OA; Patel JK; Jones I; Berman B
    Cutis; 2010 Jun; 85(6):312-7. PubMed ID: 20666193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.
    Musto P; Simeon V; Martorelli MC; Petrucci MT; Cascavilla N; Di Raimondo F; Caravita T; Morabito F; Offidani M; Olivieri A; Benevolo G; Mina R; Guariglia R; D'Arena G; Mansueto G; Filardi N; Nobile F; Levi A; Falcone A; Cavalli M; Pietrantuono G; Villani O; Bringhen S; Omedè P; Lerose R; Agnelli L; Todoerti K; Neri A; Boccadoro M; Palumbo A
    Leukemia; 2014 Jan; 28(1):222-5. PubMed ID: 23958922
    [No Abstract]   [Full Text] [Related]  

  • 10. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
    Wäsch R; Jakob T; Technau K; Finke J; Engelhardt M
    Ann Hematol; 2012 Feb; 91(2):287-9. PubMed ID: 21494796
    [No Abstract]   [Full Text] [Related]  

  • 11. Lenalidomide: Stevens-Johnson syndrome.
    Prescrire Int; 2010 Jun; 19(107):125. PubMed ID: 20740722
    [No Abstract]   [Full Text] [Related]  

  • 12. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
    Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
    Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cutaneous involvement in plasma cell leukaemia].
    Le Guern A; Farhat MM; Lebas D; Quinchon JF; Modiano P
    Ann Dermatol Venereol; 2017 Mar; 144(3):239-240. PubMed ID: 27989392
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
    Wang M; Dimopoulos MA; Chen C; Cibeira MT; Attal M; Spencer A; Rajkumar SV; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
    Blood; 2008 Dec; 112(12):4445-51. PubMed ID: 18799726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Severe skin reactions. Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema exsudativum multiforme majus and generalized bullous fixed drug exanthema].
    Rzany B; Mockenhaupt M; Baur S; Stocker U; Schöpf E
    Hautarzt; 1993 Aug; 44(8):549-54; quiz 554-6. PubMed ID: 8376113
    [No Abstract]   [Full Text] [Related]  

  • 16. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.
    Musto P; Pietrantuono G; Guariglia R; Villani O; Martorelli MC; D'Auria F; Zonno A; Lerose R
    Leuk Res; 2008 Oct; 32(10):1637-8. PubMed ID: 18433866
    [No Abstract]   [Full Text] [Related]  

  • 17. Toxic epidermal necrolysis induced by thalidomide and dexamethasone treatment for multiple myeloma.
    Hwang S; Woo Y; Kim M; Park HJ
    Int J Dermatol; 2017 Feb; 56(2):e35-e37. PubMed ID: 27805271
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients.
    Castaneda CP; Brandenburg NA; Bwire R; Burton GH; Zeldis JB
    J Clin Oncol; 2009 Jan; 27(1):156-7. PubMed ID: 19047275
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
    Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New advances in severe adverse drug reactions.
    Revuz J
    Dermatol Clin; 2001 Oct; 19(4):697-709, ix. PubMed ID: 11705355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.